

University of Groningen

## Metallo drugs for therapy and imaging: investigation of their mechanism of action

Spreckelmeyer, Sarah

**IMPORTANT NOTE:** You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

*Document Version*

Publisher's PDF, also known as Version of record

*Publication date:*

2018

[Link to publication in University of Groningen/UMCG research database](#)

*Citation for published version (APA):*

Spreckelmeyer, S. (2018). *Metallo drugs for therapy and imaging: investigation of their mechanism of action*. [Thesis fully internal (DIV), University of Groningen]. University of Groningen.

### Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license. More information can be found on the University of Groningen website: <https://www.rug.nl/library/open-access/self-archiving-pure/taverne-amendment>.

### Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): <http://www.rug.nl/research/portal>. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.

# **Propositions**

for the thesis

**Metallodrugs for Therapy and Imaging: Investigation of Their  
Mechanism of Action**

**Sarah Spreckelmeyer**

- 1) Bifunctional chelators as radiopharmaceuticals for imaging or therapy are useful tools in personalized medicine.
- 2) The milestones in cancer research could not have been achieved without the interdisciplinary work of multiple research facilities.
- 3) The combination of PET or SPECT with CT or MRI is an enormous progress in medicine.
- 4) The pharmacy study is an excellent preparation for working in an interdisciplinary environment.
- 5) Inorganic Chemistry offers a great toolbox for the design of molecules for therapy and diagnosis.
- 6) Although cisplatin is used in the clinic as anticancer agent, not much is known about its mechanism of transport.
- 7) Work hard, play hard in order to be successful in life. – adapted from James de Koven
- 8) “Um zu wissen, was im Leben wichtig ist, muss man die Welt gesehen haben.” – Marteria (“You need to have seen the world to know what is important in life.”)
- 9) The statement “Life isn’t about waiting for the storm to pass. It’s about learning to dance in the rain” (Vivian Greene) applies to the process of a PhD project.

## **Paranimphs**

Gerian Prins

Malte Schulze

Cover design: Carlos Niermeier

Layout design: Sarah Spreckelmeyer

Printed by: Ipskamp Printing

The research presented in this thesis was financially supported by CANDA. Printing of this thesis was supported by the University of Groningen, Faculty of Science and Engineering and the University Library.

ISBN (printed version): 978-94-034-0442-4

ISBN (digital version): 978-94-034-0441-7

No parts of this thesis may be reproduced or transmitted in any form or any means, electronical or mechanical, including photocopying, recording or any information storage and retrieval system, without permission of the author

## **INVITATION**

You are cordially invited to attend the public defence of the  
doctoral thesis of

SARAH SPRECKELMEYER

entitled

Metallo drugs for Therapy and Imaging – Investigation of Their  
Mechanism of Action

**Friday, 23 February 2018**

**at 16:15 hours**

Reception immediately after.

sarah.spr@gmx.de

### **Address of the defence:**

Bestuursgebouw  
Oude Boteringestraat 44  
Groningen

### **Address of the reception:**

Academiegebouw  
Broerstraat 5  
Groningen



/ university of  
 groningen



THE UNIVERSITY  
 OF BRITISH COLUMBIA

# **Metallodrugs for Therapy and Imaging: Investigation of Their Mechanism of Action**

## **PhD thesis**

to obtain the joint degree of PhD at the  
 University of Groningen and the University of British Columbia

on the authority of  
 the Rector Magnificus of the University of Groningen,  
 Prof. E. Sterken,  
 the Faculty of Graduate and Postdoctoral Studies (Chemistry) of the  
 University of British Columbia  
 and in accordance with  
 the decision by the College of Deans of the University of Groningen

This thesis will be defended in public on

Friday, 23 February 2018 at 16.15 hours

by

**Sarah Spreckelmeyer**

born on 8 May 1989  
 in Osnabrück, Germany

## **Supervisors**

Prof. G. M. M. Groothuis

Prof. C. Orvig

## **Co-supervisor**

Prof. A. Casini

## **Assessment Committee**

Prof. F. J. Dekker

Prof. M. Wolf

Prof. J. Reedijk

Für Opa Hubert



## Table of contents

<b>Introduction.....</b>	<b>13</b>
1. Metallodrugs for therapy.....	14
1.1. Pharmacology of metallodrugs for therapy.....	16
1.1.1. Pharmacokinetics (PK) and toxicity of cisplatin.....	18
1.2. Radiopharmaceuticals for therapy.....	19
1.2.1. Bifunctional chelator.....	21
1.2.1.1. Biological targets discussed in this work.....	22
1.3. Mechanism of targeting of radiopharmaceuticals for therapy...-.....	23
2. Metallodrugs for imaging.....	23
2.1. Radiopharmaceuticals.....	23
2.1.1. PET and SPECT technique.....	24
2.1.2. Mechanism of accumulation of radiopharmaceuticals for cancer imaging.....	26
2.2. Fluorescence imaging.....	27
3. References.....	28
<b>The aim of the thesis.....</b>	<b>31</b>
<b>Part A: Vancouver.....</b>	<b>36</b>
<b>A1: p-NO<sub>2</sub>-Bn-H<sub>4</sub>neunpa and H<sub>4</sub>neunpa-Trastuzumab: Bifunctional Chelator for Radiopharmaceuticals and <sup>111</sup>In Immuno-SPECT Imaging.....</b>	<b>37</b>
1. Abstract.....	38
2. Introduction.....	39
3. Results and Discussion.....	41
3.1. Synthesis and characterization of the ligand.....	41
3.2. Synthesis and characterization of non-radioactive metal complexes.....	44
3.2.1. NMR.....	44
3.2.2. IR.....	45
3.2.3. Thermodynamic stability.....	46
3.3. Radiolabeling experiments with unmodified chelator.....	51
3.4. Stability studies with unmodified chelator.....	53
3.5. Initial biodistribution studies.....	55
3.6. Preparation of Bioconjugates and in vitro characterization.....	59
3.7. Biodistribution and SPECT/CT imaging studies.....	61
4. Summary.....	66
5. Experimental.....	67

6. References.....	82
7. Supporting Information.....	88

## **A2: H<sub>4</sub>neunpa: A Bifunctional Acyclic Chelator with Many Faces.....98**

1. Abstract.....	99
2. Introduction.....	100
2.1. Subchapter 1.....	101
2.1.1. Results and Discussion.....	102
2.1.1.1. Synthesis.....	102
2.1.1.2. Radiolabeling with <sup>111</sup> In.....	103
2.1.1.3. Stability of H <sub>4</sub> neunpa-PSMA-L in human serum.....	104
2.2. Subchapter 2.....	104
2.2.1. Results and Discussion.....	106
2.2.1.1. Metallacage exo-functionalization.....	106
2.2.1.2. La-complexation reaction.....	109
2.2.1.3. Fluorescence spectroscopy.....	110
2.3. Subchapter 3.....	111
2.3.1. Results and Discussion.....	113
2.3.1.1. Radiolabeling with <sup>225</sup> Ac.....	113
2.3.1.2. <sup>225</sup> Ac/ <sup>213</sup> Bi iTLC chromatograms.....	114
2.3.1.3. Sb-complexation.....	118
3. Summary.....	119
4. Experimental.....	121
5. References.....	124
6. Supporting Information.....	127

## **A3: Tetrahydroxamic Acid Bearing Ligands: EDTA and DTPA Analogues.....134**

1. Abstract.....	135
2. Introduction.....	136
3. Results and Discussion.....	141
3.1. Synthesis and characterization.....	141
3.2. Metal complexation reactions.....	143
3.3. Infrared (IR) spectroscopy.....	144
3.4. In vitro cell experiments.....	146
3.5. Stability determination of Fe-EDT(M)HA and Fe-EDT(B)HA by UV-VIS spectroscopy.....	148
3.6. <sup>89</sup> Zr-radiolabeling.....	150
3.7. Density Functional Theory (DFT) .....	151
4. Conclusions.....	157

5. Experimental.....	158
6. References.....	166
7. Supporting Information.....	169

#### **A4: Overcoming the Limitations in Thrombosis Treatment: A Bifunctional Chelator as Positron Emission Tomography-Imaging Probe for Detecting Blood Clots.....176**

1. Abstract.....	177
2. Introduction.....	178
3. Results and Discussion.....	183
3.1. Synthesis.....	183
3.1.1. Thiol bioconjugation of compound 3.....	187
3.2. DTNB assay.....	190
4. Conclusions.....	192
5. Experimental.....	192
6. References.....	197
7. Supporting Information.....	199

### **Part B: Groningen.....204**

#### **B1: Cellular Transport Mechanisms of Cytotoxic Metallodrugs: An Overview Beyond Cisplatin.....205**

1. Abstract.....	206
2. Introduction.....	207
3. Transport processes of metal-base compounds.....	211
3.1. Anticancer Pt drugs.....	211
3.1.1. Cu transporters.....	212
3.1.2. Organic cations transporter (OCTs) and toxin extrusion proteins (MATEs).....	220
3.2. Experimental anticancer metal compounds.....	225
3.2.1. Ruthenium complexes.....	225
3.2.2. Gold complexes.....	229
3.2.3. Iridium complexes.....	234
3.3. Transporter-targeted anticancer metal compounds.....	235
4. Conclusion and Perspectives.....	237
5. References.....	238

<b>B2: Exploring the Potential of Gold(III) Cyclometallated Compounds as Cytotoxic Agents: Variations on the C<sup>N</sup> Theme.....</b>	<b>250</b>
1. Abstract.....	251
2. Introduction.....	252
3. Results and Discussion.....	253
3.1. Synthesis and structural characterization.....	254
3.2. Antiproliferative activity.....	258
3.3. PARP-1 inhibition.....	261
4. Conclusions.....	261
5. Experimental section.....	262
6. References.....	268
7. Supporting Information.....	271
<b>B3: On the Toxicity and Transport Mechanisms of Cisplatin in Kidney Tissues in Comparison to a Gold-based Cytotoxic Agent.....</b>	<b>285</b>
1. Abstract.....	286
2. Introduction.....	287
3. Results and discussion.....	292
3.1. Toxicity evaluation.....	292
3.1.1.ATP content determination.....	292
3.1.2.Histomorphology.....	294
3.1.3.Expression of kidney-injury molecule 1 (KIM-1), villin, p53 and BAX.....	298
3.2. Uptake studies.....	301
3.2.1.Metal content determination by ICP-MS.....	301
3.2.2.Effect of temperature on uptake in PCKS.....	302
4. Conclusions.....	304
5. Experimental methods.....	307
6. References.....	312
<b>B4: Investigation of the Molecular Accumulation Mechanisms of an Au(III) Cyclometallated Compound Compared to Cisplatin in vitro: Are OCT2 and CTR1 involved?.....</b>	<b>318</b>
1. Abstract.....	319
2. Introduction.....	320
3. Results and Discussion.....	323
3.1. Synthesis and characterization.....	323
3.2. Fluorescence.....	324
3.3. Antiproliferative effects.....	325
3.4. Studies of the mechanisms of transport.....	326

3.4.1.Competition experiments.....	326
3.4.2.Metal content determination.....	331
3.4.3.Passive/active mechanisms.....	338
3.5. Copper accumulation.....	340
3.6. Fluorescence microscopy.....	344
4. Conclusions.....	346
5. Experimental section.....	348
6. References.....	354
<b>General Discussion and Future Perspectives.....</b>	<b>356</b>
<b>Samenvatting.....</b>	<b>367</b>
<b>Acknowledgements.....</b>	<b>377</b>
<b>Curriculum Vitae.....</b>	<b>378</b>